Promising product of the next generation as a new anticancer drug of the selective RET inhibitor series
Fostering as a representative new drug pipeline with the goal of entering global clinical trials in 2022
[바이오타임즈] Inno.N announced on the 15th that it will start developing global anticancer drugs by introducing non-clinical anticancer drugs from Voronoi, a company specializing in new drug research and development. The goal is to enter the global clinical trial next year.
‘VRN061782’, a new anticancer drug introduced from Voronoi, is a selective RET (Rearranged During Transfection) kinase inhibitor, in order to take the development of new anticancer drugs as a key growth engine by Innoen. Inhibits the activity of this gene when it causes cancer or when cancer is caused by binding to another gene
The anticancer drug line is a next-generation line with only two products in the world. It is also considered a promising market that is expected to grow to about 2 trillion won in 2026. Innoen plans to grow this substance into one of the leading new drug pipelines to compete in the global market with the aim of entering global clinical trials in 2022.
Previously, when cancer occurred due to a problem with the RET gene, there was no suitable treatment, so a’non-selective kinase treatment’ that attacks other genes as well as the RET gene was used as a substitute. However, due to the low drug response rate and side effects, recently, anticancer drugs of a selective RET inhibitor group that inhibit only RET gene activity, such as Lily Celpercatinib and Roche Pralcetinib, have begun to appear.
The candidate material showed a higher response to drug resistance than competing drugs of the same class in nonclinical animal tests, and excellent cardiovascular safety was also confirmed by selecting and attacking only specific genes.
Innoen plans to introduce a new drug with differentiated efficacy, tolerance, and safety by developing a customized target anticancer drug that selectively targets only cancer cells with the same internal indicator (biomarker).
Innoen’s CEO Seok-Hee Kang said, “Our goal is to quickly enter the global anticancer market through the synergy of Voronoi’s excellent new drug candidate research capabilities and Innoen’s new drug development capabilities.” We plan to secure the pipeline of the company.”
[바이오타임즈=강철현 기자] [email protected]
Copyright © BioTimes Unauthorized reproduction and redistribution prohibited